Effect of hyperthermic intraperitoneal chemotherapy (HIPEC) on postoperative immune function and tumor marker levels in patients with advanced gastric adenocarcinoma
10.3760/cma.j.cn431274-20250910-01165
- VernacularTitle:腹腔热灌注化疗对进展期胃腺癌患者术后免疫功能和肿瘤标志物水平的影响
- Author:
Guoxi XU
1
;
Qiyi LIN
1
;
Zhicong CAI
1
;
Meiyun LIN
1
;
Bizhuan FU
1
;
Huaishuai WANG
1
;
Yixiang ZHUANG
1
;
Tao GUO
1
Author Information
1. 晋江市医院（上海市第六人民医院福建医院）胃肠、疝与腹壁外科，泉州 362200
- Publication Type:Journal Article
- Keywords:
Gastric adenocarcinoma;
Hyperthermic intraperitoneal chemotherapy;
Biomarkers, tumor;
Immune function
- From:
Journal of Chinese Physician
2025;27(10):1464-1467
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) on postoperative immune function and tumor marker levels in patients with advanced gastric adenocarcinoma.Methods:A prospective cohort study was conducted, enrolling 72 patients with stage ⅢA-ⅢC gastric adenocarcinoma admitted to Jinjiang Hospital from August 2022 to December 2023. Patients were divided into the HIPEC group ( n=36, radical resection+ HIPEC within 3 days after surgery) and the control group ( n=36, radical resection alone) using the random number table method. The HIPEC protocol was perfusion with raltitrexed (4 mg in 4, 000 ml normal saline, at 43 ℃) for 60 minutes. Peripheral blood immune cells (CD3 +, CD4 +, CD8 +, CD4 + /CD8 + ratio) before treatment and 7 days after treatment, and serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 72-4 (CA72-4) 30 days after treatment were compared between the two groups. Results:Before treatment, there were no statistically significant differences in CD3 +, CD4 +, CD8 +, or CD4 + /CD8 + levels between the two groups (all P>0.05). Seven days after treatment, the HIPEC group had higher levels of CD3 +, CD4 +, and CD4 + /CD8 + ratio, and a lower CD8 + level than the control group, with statistically significant differences (all P<0.05). Before treatment, there were no significant differences in CEA, CA19-9, or CA72-4 levels between the two groups (all P>0.05). Thirty days after treatment, the HIPEC group had lower levels of CEA, CA19-9, and CA72-4 than the control group, with statistically significant differences (all P<0.05). Conclusions:HIPEC can significantly improve the postoperative immune function of patients with advanced gastric adenocarcinoma (by increasing the CD4 + /CD8 + ratio and immune cell activity) and effectively reduce tumor marker levels, which may provide a new strategy for preventing postoperative recurrence.
